Oculis Holding AG - Ordinary shares (OCS)

Oculis (NASDAQ:OCS) said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug candidate in that indication. Chief Executive Officer Riad Sher

Oculis (OCS) beat Q3 2025 earnings estimates, extended cash runway into 2029, and advanced its late-stage ophthalmology pipeline with key clinical milestones ahead.

OCS stock results show that Oculis Holding missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

U.S. stock futures were slightly higher this morning, with the Dow Jones futures gaining around 15 points on Thursday. Shares of FLJ Group Limited(NASDAQ: FLJ) rose sharply in pre-market trading.